Ionis announces the appointment of Michael Yang to Board of Directors
CARLSBAD, Calif., Dec. 14, 2023 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the appointment of Michael Yang, an experienced biopharmaceutical executive, to the Ionis Board of Directors. Mr. Yang’s appointment expands the total number of Ionis Board members to 10.
Related news for (IONS)
- Midday Movers: Biotech Breakouts, Special Payouts, and Strategic Power Plays
- Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy
- Ionis to hold fourth quarter and full year 2023 financial results webcast
- Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases
- WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis